The study is being conducted at Basel in Switzerland under a clinical trial application approved by SwissMedic, the regulatory authority of the country. The study is expected to be completed by December 2008. The company targets to launch the molecule in 2012.
According to Suven Chief Executive Officer Venkat Jasti, SUVN-502 is the first NCE (new chemical entity) of the company to enter the clinical trials from a pipeline of six NCEs. The CNS (central nervous system) market worldwide is of the order $20 billion.
Suven's Vice President (Discovery Research) Ramakrishna Niyogi stated that the company was also in discussions for potential licensing partners for the compound. Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets, he added.
